No.

PL 3070/0007

Coy.

Speywood Labs Ltd

Product

Hyate: C

Therapeutic Class

Porcine Blood Product

Active Constituent

Porcine Factor VIII:C

Main Committee 22/23.3.84

Advice

On the evidence before them the Committee advised the grant of a Product Licence for this preparation on condition that:

1. clarification was provided on certain aspects of the manufacturing process, with particular reference to: blood collection; initial processing; sterilisation of plastic bags; changes made to the manufacturing/control processes and Finished Product Specifications over the period of time the product has been in clinical use; the choice of molar ratio used in the polyelectrolyte; and on the in process levels of extractables,

2. full details were provided of the Factor VIII standards used in the assay of the product, that is both the "in-house" standard and that supplied by Diagnostic Reagents Ltd.,

3. data from the accelerated stability study were provided along with details of how these and standard stability tests on an on-going basis will be undertaken,

4. the limits applied to the following were tightened or justified:

i) Factor VIII:C activity,
ii) Platelet aggregating activity,
iii) Residual polyethylene glycol,
iv) Aluminium

Remark

1. In the event of a Product Licence being granted the Committee considered that:

1.1 the licence should be conditional on satisfactory inspection reports from the factory and the abbatoir, with particular reference to the use of the proposed blood collection technology,

1.2 the Company should be encouraged to set up post-marketing surveillance studies to monitor the long-term safety of Hyate: C,

1.3 a full stop-on-sale order should be applied to all batches of the product and should include the provision of bulks and in-process samples. The company should supply the Secretariat with details of the assay procedures agreed with the National Institute of Biological Standards and Control.

No.

PL/3070/0007

Coy.

Speywood Laboratories Ltd

Product

Hyate: C

Therapeutic Class

Blood Product

Active Constituent

Porcine Factor VIII:C

SUB-COMMITTEE ON BIOLOGICAL PRODUCTS — 7 MARCH 1984

RECOMMENDATION

On the evidence before them the Sub-Committee, on grounds of safety and quality, were unable to recommend the grant of a Product Licence for this product.

The Sub-Committee considered that:

1. there was insufficient evidence of safety in long-term use for the propylamine extractables present in the product,

2. the Company should justify the aluminium levels in the finished product and demonstrate that these levels do not provide a toxic hazard in clinical use,

3. clarification should be provided on certain aspects of the manufacturing process, with particular reference to: blood collection; initial processing; sterilisation of plastic bags; changes made to the manufacturing/control processes and Finished Product Specifications over the period of time the product has been in clinical use; the choice of molar ratio used in the polyelectrolyte; and on the in process levels of extractables,

4. full details should be provided of the Factor VIII standards used in the assay of the product, that is both the "in-house" standard and that supplied by Diagnostic Reagents Ltd.,

5. data from the accelerated stability study should be provided along with details of how these and standard stability tests on an on-going basis will be undertaken,

6. justification should be provided for the limits applied to:

   i) Factor VIII:C activity,
   ii) Platelet aggregating activity,
   iii) Residual polyethylene glycol,
   iv) Aluminium

Remarks

1. in the event of a Product Licence being granted the Sub-Committee considered that:

   1.1 the licence should be conditional on satisfactory inspection reports from the factory and the abbatoir, with particular reference to the use of the proposed blood collection technology,

   1.2 the Company should be encouraged to set up post-marketing surveillance studies to monitor the long-term safety of Hyate: C,

No.

PL/3070/0007

Coy.

Speywood Laboratories Ltd

Product

Hyate: C

Therapeutic Class

Blood Product

Active Constituent

Porcine Factor VIII:C

1.3 a full stop-on-sale order should be applied to all batches of the product, to include the provision of bulks and in-process samples. The company should supply the Secretariat with details of the assay procedures agreed with the National Institute of Biological Standards and Control.

Remark to SEAR

2. the Sub-Committee would look more favourably on an application for a Clinical Trial Certificate, provided it was recognised that long term toxicity data would need need to be available by the PL stage.